Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Neurology

• Publication date

  2015-06-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-015-7798-0PMID 26041617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain atrophy in natalizumab-treated patients: A 3-year follow-up

  2015cited by this paper
• Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

  2015cited by this paper
• Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

  2014cited by this paper
• In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells.

  2014cited by this paper
• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cited by this paper
• Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

  2014cited by this paper
• Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

  2014cited by this paper
• Brain atrophy as a non-response predictor to interferon-beta in relapsing–remitting multiple sclerosis

  2014cited by this paper
• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cited by this paper
• A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

  2014cited by this paper
• Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

  2013cited by this paper
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis

  2013cited by this paper
• Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

  2013influential reference
• Clinical impact of early brain atrophy in clinically isolated syndromes

  2013cited by this paper
• Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

  2013cited by this paper
• Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing–remitting multiple sclerosis: a prospective, 
non‐randomized pilot study

  2013cited by this paper
• Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

  2013cited by this paper
• Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

  2013cited by this paper
• Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

  2013cited by this paper
• Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

  2013cited by this paper
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

  2012cited by this paper
• The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.

  2012cited by this paper
• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

  2012cited by this paper
• Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

  2012cited by this paper
• Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis

  2012cited by this paper
• Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

  2012cited by this paper
• Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

  2012cited by this paper
• Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

  2012cited by this paper
• Placebo-controlled trial of oral laquinimod for multiple sclerosis.

  2012cited by this paper
• Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

  2011cited by this paper
• Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

  2011cited by this paper
• Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis

  2011cited by this paper
• Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

  2011cited by this paper
• Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures

  2010cited by this paper
• The mechanism of action of glatiramer acetate treatment in multiple sclerosis

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Interferon-β mechanisms of action in multiple sclerosis

  2010cited by this paper
• Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

  2010cited by this paper
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

  2009cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008influential reference
• Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

  2008cited by this paper
• Central nervous system-directed effects of FTY720 (fingolimod).

  2008cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors

  2007cited by this paper
• MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

  2007cited by this paper
• Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

  2007cited by this paper
• Natalizumab for multiple sclerosis.

  2007cited by this paper
• I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy

  2007cited by this paper
• Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

  2007cited by this paper
• Guidelines for using proton MR spectroscopy in multicenter clinical MS studies

  2007cited by this paper
• Multiple sclerosis--the plaque and its pathogenesis.

  2006cited by this paper
• The measurement and clinical relevance of brain atrophy in multiple sclerosis.

  2006cited by this paper
• Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS

  2006cited by this paper
• Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a

  2005cited by this paper
• Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole‐Brain Atrophy Measurement in Multiple Sclerosis

  2005cited by this paper
• Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

  2004cited by this paper
• Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

  2004cited by this paper
• Interferon-&bgr;-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb− and NAb+ patients

  2004cited by this paper
• A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta

  2002cited by this paper
• Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis

  2002cited by this paper
• Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.

  2002cited by this paper
• Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.

  2001cited by this paper
• Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS

  2000cited by this paper
• Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a

  2000cited by this paper
• Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation?

  1999cited by this paper
• For Personal Use. Only Reproduce with Permission from Elsevier Ltd Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: a Randomised, Double-blind, Placebo-controlled Trial

  year unknowncited by this paper

• Microglia and Multiple Sclerosis.

  2024cites this paper
• Age-related decline in cerebral oxygen consumption in multiple sclerosis

  2024cites this paper
• Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset

  2023cites this paper
• Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression

  2022cites this paper
• Disrupted neural correlates of anesthesia and sleep reveal early circuit dysfunctions in Alzheimer models

  2022cites this paper
• Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score

  2020cites this paper
• Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process

  2020cites this paper
• MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

  2020cites this paper
• Introductory Chapter: Multiple Sclerosis

  2020cites this paper
• Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.

  2019cites this paper
• Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis

  2019cites this paper
• Mitochondrial Regulation of the Hippocampal Firing Rate Set Point and Seizure Susceptibility

  2019cites this paper
• Therapeutic Advances in Neurological Disorders

  2019cites this paper
• Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study

  2018cites this paper
• Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.

  2018cites this paper
• Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS

  2018cites this paper
• “Brain reserve” and “cognitive reserve” should always be taken into account when studying neurodegeneration – NO

  2018cites this paper
• Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.

  2018cites this paper
• Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

  2018cites this paper
• Brain volume in early MS patients with and without IgG oligoclonal bands in CSF.

  2018cites this paper
• Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations

  2018cites this paper
• Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2—Surveillance for Treatment Complications and Disease Progression

  2017cites this paper
• Grey matter atrophy is associated with disability increase in natalizumab-treated patients

  2017cites this paper
• MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis.

  2017cites this paper
• Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects.

  2017cites this paper
• A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.

  2017influential citation
• Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.

  2017cites this paper
• Teriflunomide slows BVL in relapsing MS

  2017influential citation
• A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis

  2017cites this paper
• Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis.

  2016cites this paper
• Brain parenchymal fraction in healthy individuals and in clinical follow-up of multiple sclerosis

  2016cites this paper
• Brain atrophy measurements should be used to guide therapy monitoring in MS – NO

  2016cites this paper
• Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

  2016cites this paper
• The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis

  2016cites this paper
• MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.

  2016cites this paper
• Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review

  2015cites this paper
• Optimizing treatment success in multiple sclerosis

  2015cites this paper